Vaishali Pharma Limited (NSE: VAISHALI)

By Raveendran R | Updated on:

Source: Vaishali Pharma Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners

Vaishali Pharma Limited is an established enterprise operating in the global healthcare and pharmaceutical sector, focusing primarily on the marketing, trading, and export of a diverse portfolio of medical and healthcare products. The Company’s core business model spans multiple specialized verticals, enabling it to address varied healthcare requirements across domestic and international markets.

CORE BUSINESS SEGMENTS:
  • Active Pharmaceutical Ingredients (APIs): High-purity active raw materials supplied to formulation manufacturers.
  • Formulations: Finished pharmaceutical dosage forms including tablets, capsules, syrups, injectables, and ointments.
  • Surgical Products: Comprehensive medical disposables and surgical consumables utilized in clinical settings.
  • Veterinary Supplements: Specialized healthcare and nutritional formulations designed for animal husbandry.
Metrics for FY 2025-26 Ended Mar 31, 2026

📋 Quick Facts / Company Snapshot: Vaishali Pharma Limited (NSE: VAISHALI)

Attribute Disclosed Detail
Official Company Name Vaishali Pharma Limited
Corporate Identity Number (CIN) L52310MH2008PLC181632
ISIN INE972X01022
NSE Symbol & BSE Scrip Code NSE: VAISHALI
Date of Incorporation / Founding Year 25th April, 2008
Founders / Key Founding Figures Mr. Atul Arvind Vasani and Mrs. Jagruti Atul Vasani
Registered Office & Corporate Headquarters 706 to 709, 7th Floor, Aravali Business Center, R. C. Patel Road, Off Sodawala Lane, Borivali (West), Mumbai – 400092, Maharashtra, India
Telephone & Investor Relations Contact cs@vaishalipharma.com
Chairman / Managing Director & CEO Mr. Atul Vasani (Chairman & Managing Director), Mr. Hemant Damodar Pathak (Chief Executive Officer)
Chief Financial Officer (CFO) & Company Secretary (CS) Mr. Dewansh Ajay Vasani (CFO), Ms. Vishwa Bipinbhai Mekhia (Company Secretary & Compliance Officer)
Promoter & Holding Group Mr. Atul Arvind Vasani and Mrs. Jagruti Atul Vasani
Industry / Sector Classification Pharmaceuticals, Healthcare, and Allied Products Sector
Total Employees / Workforce 30 Permanent employees on the rolls as on March 31, 2026
Countries / States Served Domestic markets across India and international markets including Russia, the UAE, Madagascar, and Palestine
Statutory Auditors Raman S. Shah & Associates, Chartered Accountants
Registrar and Share Transfer Agent (RTA) Bigshare Services Private Limited

🏢 The Corporate Identity: Vaishali Pharma Limited Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Vaishali Pharma Limited is an established enterprise operating in the global healthcare and pharmaceutical sector, focusing primarily on the marketing, trading, and export of a diverse portfolio of medical and healthcare products. The Company’s core business model spans multiple specialized verticals, enabling it to address varied healthcare requirements across domestic and international markets. By leveraging its extensive supply chain network, stringent quality assurance protocols, and established customer relationships, Vaishali Pharma Limited delivers reliable and cost-effective pharmaceutical solutions.

The enterprise functions as a comprehensive sourcing and distribution partner within the pharmaceutical ecosystem, bridging manufacturers and end-users across emerging and regulated international geographies. Through continuous process improvements, regulatory compliance, and strategic product diversification, the Company maintains a resilient operational framework designed to generate sustainable, long-term value for its stakeholders.

The Founders, Promoters & Their Legacy

The strategic direction and operational leadership of Vaishali Pharma Limited are steered by its promoter directors, Mr. Atul Arvind Vasani, who serves as the Chairman and Managing Director, and Mrs. Jagruti Atul Vasani, who serves as the Whole-Time Director. Their extensive experience in the pharmaceutical trading and export industry has been instrumental in guiding the Company through evolving market dynamics, global economic shifts, and regulatory transformations.

Supported by a professional executive management team—including Mr. Dewansh Ajay Vasani as Executive Director and Chief Financial Officer, and Mr. Hemant Damodar Pathak as Chief Executive Officer—the promoter group has cultivated a culture of integrity, transparency, and accountability. This leadership foundation has enabled the organization to forge durable commercial relationships and expand its operational footprint across multiple international territories.

The Journey: Corporate History & Key Milestones

Incorporated on April 25, 2008, as a private limited company under the provisions of the Companies Act, 1956, Vaishali Pharma Limited subsequently transitioned into a public limited company to support its expanding business scale. Over the years, the Company has systematically broadened its product offerings from basic pharmaceutical formulations to a comprehensive suite encompassing Active Pharmaceutical Ingredients (APIs), surgical products, veterinary supplements, and herbal and nutraceutical preparations.

A significant milestone in the Company’s capital market history includes the listing of its equity shares on the National Stock Exchange of India Limited (NSE) under the trading symbol VAISHALI. Further expanding its strategic footprint, during the financial year 2025–26, the Company increased its equity shareholding in Kesar Pharma Limited from 11.30% to 20.33%, establishing it as an associate company with effect from September 10, 2025.

The Corporate Umbrella & Group Structure

As of March 31, 2026, Vaishali Pharma Limited operates as a standalone corporate entity with one associate company within its structural umbrella. The Company does not have any direct subsidiaries or joint venture entities as of the reporting date. The associate entity, Kesar Pharma Limited, operates within the pharmaceutical manufacturing and allied domain, contributing to the broader strategic synergies of the group.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Vaishali Pharma Limited operates primarily within a single unified business segment focused on the trading, marketing, and export of pharmaceutical and healthcare products. Consequently, discrete segment-wise reporting for distinct business verticals is not separately maintained under Ind AS 108, as the entire operations are viewed by the chief operating decision maker as a single reportable operating segment.

The Product & Service Catalog (and Operational KPIs)

The Company maintains a diversified product catalog designed to cater to human healthcare, veterinary care, and surgical requirements. Its product segments comprise Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations across various dosage forms, surgical dressings and hospital consumables, veterinary dietary supplements, and herbal and nutraceutical health products.

  • Active Pharmaceutical Ingredients (APIs): High-purity active raw materials supplied to formulation manufacturers.
  • Formulations: Finished pharmaceutical dosage forms including tablets, capsules, syrups, injectables, and ointments.
  • Surgical Products: Comprehensive medical disposables and surgical consumables utilized in clinical settings.
  • Veterinary Supplements: Specialized healthcare and nutritional formulations designed for animal husbandry.
  • Herbal & Nutraceutical Products: Plant-based remedies and nutritional health supplements supporting holistic wellness.

Mapping the Domestic & Global Reach (India vs. Exports)

Vaishali Pharma Limited maintains a balanced commercial presence across domestic Indian markets and international territories. International operations are characterized by exports to several emerging global economies, supported by established logistics and regulatory compliance frameworks.

Market Geography Revenue (₹ in Crores) % Share of Total Revenue
Domestic Sales (India) 64.99 57.71%
Export Sales (International) 39.77 35.32%
Commission Income & Export Incentives 4.02 3.57%
Total Income from Operations 112.61 100.00%

Note: International export destinations serviced by the Company include Russia, the United Arab Emirates (UAE), Madagascar, Palestine, and other emerging global markets.

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The Company’s registered and corporate office is strategically situated at Borivali West, Mumbai, Maharashtra, providing centralized administrative control, corporate governance oversight, and commercial coordination. Operational logistics, sourcing, and quality control functions are managed through established commercial channels and partnered manufacturing infrastructure.

📊 The Financial Health: The Numbers Simplified

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

The consolidated financial performance of Vaishali Pharma Limited for the financial year ended March 31, 2026, reflects steady top-line expansion and improved operational profitability compared to preceding periods.

Financial Particulars (₹ in Crores) FY 2025-26
Revenue from Operations 108.77
Other Income 3.84
Total Income 112.61
Purchases of Stock-in-Trade / Cost of Materials Consumed 93.71
Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress 1.41
Employee Benefits Expense 2.91
Finance Costs 1.96
Depreciation and Amortisation Expense 0.60
Other Expenses 6.62
Total Expenses 107.22
Profit Before Tax 5.39
Tax Expense (Current Tax & Deferred Tax) 1.36
Profit After Tax (PAT) 4.16
Share of Profit from Associate Company 0.13
Other Comprehensive Income (OCI) (Net of Tax) 0.03
Total Comprehensive Income for the Year 4.20
Basic & Diluted Earnings Per Share (EPS in ₹) 0.32

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The consolidated financial position of the group as at March 31, 2026, details a robust asset base supported by working capital lines and shareholder equity.

Balance Sheet Particulars (₹ in Crores) As at March 31, 2026
Property, Plant and Equipment 0.90
Right of Use Assets 0.26
Intangible Assets & Intangible Assets under Development 0.79
Non-Current Investments 5.56
Other Non-Current Financial & Non-Financial Assets 2.92
Deferred Tax Assets (Net) 0.15
Total Non-Current Assets 10.43
Inventories 3.40
Trade Receivables 50.77
Cash and Cash Equivalents 1.11
Bank Balances Other than Cash and Cash Equivalents 0.32
Other Current Financial Assets 32.09
Current Tax Assets (Net) & Other Current Assets 25.27
Total Current Assets 112.96
Total Assets 123.39
Equity Share Capital 26.09
Other Equity 43.02
Total Equity 69.12
Non-Current Borrowings 5.69
Non-Current Provisions 0.29
Total Non-Current Liabilities 5.98
Current Borrowings 12.84
Current Lease Liabilities 0.36
Trade Payables 21.18
Other Current Financial & Non-Financial Liabilities 12.47
Current Provisions & Income Tax Liabilities 1.45
Total Current Liabilities 48.30
Total Liabilities 54.28
Total Equity and Liabilities 123.39

Cash Flow: Tracking the Money Movement

The consolidated statement of cash flows highlights the generation and utilization of liquid resources across operating, investing, and financing activities during the fiscal year.

Cash Flow Particulars (₹ in Crores) Year ended March 31, 2026
Net Cash from Operating Activities 0.44
Net Cash Used in Investing Activities (5.46)
Net Cash from Financing Activities 4.61
Net Increase / (Decrease) in Cash and Cash Equivalents (0.41)
Cash and Cash Equivalents at Beginning of Year 1.84
Cash and Cash Equivalents at End of Year 1.43

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The Board of Directors comprises experienced professionals across executive and independent capacities, ensuring robust governance and adherence to regulatory standards.

Name of Director / KMP Designation / Role DIN Category
Mr. Atul Arvind Vasani Chairman & Managing Director 02107085 Executive Director
Mrs. Jagruti Atul Vasani Whole-Time Director 02107094 Executive Director
Mr. Dewansh Ajay Vasani Executive Director & Chief Financial Officer 08111804 Executive Director
Mr. Manish Bhagwandas Ved Non-Executive Independent Director 08654674 Independent Director
Mr. Pratik Vikram Jakhelia Non-Executive Independent Director 07726752 Independent Director
Mr. Bhaveshkumar Popatlal Upadhyay Non-Executive Independent Director 08384922 Independent Director
Mr. Hemant Damodar Pathak Chief Executive Officer — Key Managerial Personnel
Ms. Vishwa Bipinbhai Mekhia Company Secretary & Compliance Officer — Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

The shareholding distribution of Vaishali Pharma Limited as on March 31, 2026, reflects promoter commitment alongside institutional and public retail participation.

Category of Equity Shareholder Number of Equity Shares Held Percentage of Holding (%)
Promoters (Mr. Atul Arvind Vasani & Mrs. Jagruti Atul Vasani) 4,12,35,290 31.61%
Non-Resident Indians (NRIs) / OCBs / Foreign Nationals 445,480 0.34%
Bodies Corporates (Non-Institutional) 35,09,810 2.69%
Indian Public and Others 8,49,59,452 65.12%
Clearing Members 312,098 0.24%
Grand Total 13,04,62,130 100.00%

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

In accordance with Form AOC-1, the Company holds an associate stake in Kesar Pharma Limited as of March 31, 2026.

Name of Associate Entity Relationship Country % Shareholding Latest Audited Net Worth (₹)
Kesar Pharma Limited Associate Company India 20.33% ₹29,58,02,340

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

The Company derives its competitive strength from a diversified product portfolio, established global sourcing networks, and enduring relationships with customers across multiple international jurisdictions. Its ability to supply specialized pharmaceutical formulations, APIs, and surgical products provides operational flexibility in responding to shifting healthcare demands.

What Could Go Wrong? Key Challenges & Business Risks

Key business risks identified by the management include foreign exchange rate volatility, regulatory developments across export markets, supply chain disruptions, pricing pressures, and intense competition within the pharmaceutical trading sector. The Company actively monitors these risk factors through prudent financial management and structured internal control mechanisms.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Looking ahead, Vaishali Pharma Limited remains focused on expanding its international market presence, optimizing operational efficiencies, strengthening its core product portfolio, and identifying new avenues for long-term revenue growth. Strategic investments, such as its association with Kesar Pharma Limited, align with the organization’s broader objective of building a resilient and globally competitive healthcare enterprise.

The Verdict: Strategic Outlook & Conclusion

Through disciplined financial governance, rigorous quality assurance, and continued geographical diversification, Vaishali Pharma Limited is well-positioned to capitalize on emerging opportunities within the global pharmaceutical ecosystem while delivering sustainable value to its stakeholders.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.vaishalipharma.com

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]

SCHEMA

[googlesitekit-end-of-content]